Purpose

The Alzheimer's disease pathological peptide Aβ can affect blood clotting but a mechanism for this action is not fully understood. To investigate this effect further we will use an test tube assay for clotting to determine how Aβ interacts with both fibrin and platelets in human blood. Using this assay we have already observed that Aβ binds to a collagen surface when fibrin is present and that platelets bind to Aβ forming clots that are more stable than those formed in the absence of Aβ. We will use this clotting assay with real time imaging to explore how different structural forms and known mutants of Aβ alter clot formation and structure through their interaction with platelets and fibrin.

Condition

Eligibility

Eligible Ages
Between 45 and 75
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy volunteers between 45 and 75 years of age free of any medication (excluding contraceptives) or alcohol for at least 24 hours before donation

Exclusion Criteria

  • Healthy volunteers with self-reported significant medical conditions such as Alzheimer's disease or history of stroke or cancer.
  • Current daily use of anti-platelet aggregation medications (Plavix or aspirin for example) or blood thinning/anticoagulant medications.
  • Ingestion of NSAIDs or apirin within 2 weeks of enrollment.
  • Current smoker or vaper (within 7 days of study visit)
  • Needle phobia
  • Any medical psychological or social condition that in the opinion of the Investigator would jeopardize the health or well-being of the participant or the integrity of the data

Study Design

Phase
Study Type
Observational

More Details

Status
Recruiting
Sponsor
Rockefeller University

Study Contact

Recruitment Office
8007822737
rucares@rockefeller.edu

Notice

Study information shown on this site is derived from this institution's local clinical trials team. The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.